In vivo experiments in AD transgenic mice also verified that after treating with β2-AR agonist isoproterenol for a long time, the Aβ plaque enhanced in the mouse brain and on the contrary antagonist ICI118551 reduced the plaque [26]. This evidence concerns the gene ADRB2 and Alzheimer disease.